Clinical Trials
2
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2010
No trial phase data available
Completed
1
50.0%
Recruiting
1
50.0%
No approval data available
- A groundbreaking CAR-T cell therapy targeting CD30 protein (HSP-CAR30) has achieved a 100% overall response rate in patients with refractory CD30+ lymphoma, with 50% achieving complete remission. - The Phase I clinical trial demonstrated remarkable durability, with 60% of complete responders remaining in remission after a median follow-up of 34 months, and CAR30+ cells persisting in 60% of evaluable patients one year post-infusion. - Developed by researchers at Sant Pau Research Institute in collaboration with Sant Pau Hospital and Josep Carreras Leukaemia Research Institute, this first successful European CAR-T30 study offers new hope for patients with limited treatment options.
- International researchers have developed a promising TIM-3 decoy mechanism that prevents B-ALL tumor cells from deactivating CAR-T cells, potentially addressing the high relapse rate in current treatments. - The innovative approach targets the galectin-9/TIM-3 immune checkpoint pathway, which B-ALL tumors exploit to evade immune response, with CAR-T cells engineered to secrete TIM-3 decoy showing improved anti-leukemia effectiveness in preclinical models. - Though still in preclinical stages, this breakthrough from the Josep Carreras Leukaemia Research Institute and Hospital Universitario 12 de Octubre-CNIO collaboration could lead to "armored CAR-T cells" with applications beyond B-ALL to solid tumors.
